Maika Heffernan

TL;DR: Monthly infusions of pamidronate provide significant protection against skeletal complications and improve the quality of life of patients with stage III multiple myeloma.

TL;DR: In this paper, pamidronate disodium (90 mg) was given to women with stage IV breast cancer who were receiving cytotoxic chemotherapy and had at least one lytic bone lesion.

TL;DR: Pamidronate therapy has been shown to reduce skeletal complications effectively for up to 12 months in breast carcinoma patients with bone metastases as discussed by the authors, and the results of two randomized, multicenter, randomized, double-blind, placebo-controlled intervention trials conducted at academic and community oncology centers were combined to provide a large data set with which to evaluate the long term efficacy and safety of pamidroneate therapy.

TL;DR: Long-term monthly infusions of pamidronate as an adjunct to chemotherapy are superior to chemotherapy alone in reducing skeletal events in stage III multiple myeloma patients, and may improve the survival of patients on salvage therapy.

TL;DR: The risk for osteolytic bone lesion complications in metastatic breast cancer was significantly decreased with monthly infusions of 90 mg of pamidronate, and this effect was maintained for at least 2 years.